Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report)’s stock price fell 3.5% on Friday . The stock traded as low as $12.20 and last traded at $12.63. 13,543 shares traded hands during mid-day trading, a decline of 96% from the average session volume of 308,243 shares. The stock had previously closed at $13.09.
Analyst Ratings Changes
A number of equities analysts have weighed in on CNTA shares. Morgan Stanley boosted their price target on Centessa Pharmaceuticals from $8.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Friday, June 21st. Oppenheimer reaffirmed an “outperform” rating and set a $14.00 price target on shares of Centessa Pharmaceuticals in a research report on Wednesday.
View Our Latest Analysis on Centessa Pharmaceuticals
Centessa Pharmaceuticals Price Performance
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). On average, research analysts forecast that Centessa Pharmaceuticals plc will post -1.62 earnings per share for the current year.
Hedge Funds Weigh In On Centessa Pharmaceuticals
A number of institutional investors have recently modified their holdings of CNTA. Quarry LP bought a new position in Centessa Pharmaceuticals in the fourth quarter valued at about $48,000. EntryPoint Capital LLC bought a new position in shares of Centessa Pharmaceuticals in the first quarter worth about $109,000. Sandia Investment Management LP acquired a new stake in shares of Centessa Pharmaceuticals in the 2nd quarter valued at approximately $90,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 69.2% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock valued at $122,000 after purchasing an additional 4,423 shares during the last quarter. Finally, Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals during the 2nd quarter worth approximately $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.
About Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.
Featured Stories
- Five stocks we like better than Centessa Pharmaceuticals
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
- Buy P&G Now, Before It Sets A New All-Time High
- Warren Buffett’s Recent Stock Moves: Top Buys and Sells to Watch
- How to Use Stock Screeners to Find Stocks
- Sea Limited’s E-Commerce and Fintech Strength Fuel Stock Surge
Receive News & Ratings for Centessa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centessa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.